673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
| Autor: | Schoeffski, P., Lorusso, P., Yamamoto, N., Lugowska, I., Moreno Garcia, V., Lauer, U., Hu, C., Jayadeva, G., Lahmar, M., Gounder, M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S472-S473 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|